» Articles » PMID: 22142341

Comparative Effect of Pre-coseasonal and Continuous Grass Sublingual Immunotherapy in Children

Overview
Journal Allergy
Date 2011 Dec 7
PMID 22142341
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: One of the most important aspects of sublingual immunotherapy (SLIT) is the regimen of administration. The aim of the study was to compare the efficacy and the safety of SLIT given pre-coseasonally (starting before the pollen season and continuing until the end of it) and continuously (all year round, independent of the pollen season) in children allergic to grass pollen.

Methods: Sixty children aged 6-18, sensitive only to grass pollen, with rhinitis (20 patients had concomitant asthma) participated in the 2-year prospective, randomized, double-blind, placebo-controlled trial.

Results: Both pre-coseasonal and continuous SLIT were associated with a substantial reduction in the combined symptoms/medication score when compared with placebo; there were no significant differences between the regimens (mean difference: 18.1 ± 12.4, P > 0.05). Similar changes were observed in the total symptoms score. Pre-coseasonal therapy, compared with continuous, was more effective in the reduction of nasal symptoms (mean difference: -18.0 ± 2.5, P = 0.006). We did not observe significant differences in medication, ocular, and asthma scores between the regimens. We did not observe changes in morning PEF, FEV1, and PD20 in any of the three groups nor between the groups throughout the study. We showed a significant decrease in FeNO level comparable in both active groups. There were no differences between groups in the induction of CD4CD25Foxp3-positive cells in peripheral blood during the study.

Conclusion: Both protocols were effective compared with placebo and showed similar decreases for combined symptoms/medication score and all secondary endpoints, with the exception of nasal symptoms that were lower in the pre-coseasonal group.

Citing Articles

Clinical Practice Guideline: Immunotherapy for Inhalant Allergy.

Gurgel R, Baroody F, Damask C, Mims J, Ishman S, Baker Jr D Otolaryngol Head Neck Surg. 2024; 170 Suppl 1:S1-S42.

PMID: 38408152 PMC: 11788925. DOI: 10.1002/ohn.648.


Efficacy and safety of sublingual versus subcutaneous immunotherapy in children with allergic rhinitis: a systematic review and meta-analysis.

Yang J, Lei S Front Immunol. 2024; 14:1274241.

PMID: 38162647 PMC: 10757840. DOI: 10.3389/fimmu.2023.1274241.


Efficacy and safety of sublingual immunotherapy for allergic rhinitis: A network meta-analysis.

Ji Z, Jiang F Front Immunol. 2023; 14:1144816.

PMID: 37063866 PMC: 10097890. DOI: 10.3389/fimmu.2023.1144816.


Safety, Efficacy, and Preventive Role of Subcutaneous and Sublingual Allergen Immunotherapy for the Treatment of Pediatric Asthma.

Giannetti A, Ricci G, Procaccianti M, Santoro A, Caffarelli C J Asthma Allergy. 2020; 13:575-587.

PMID: 33204114 PMC: 7667503. DOI: 10.2147/JAA.S234280.


Sublingual immunotherapy for asthma.

Fortescue R, Kew K, Leung M Cochrane Database Syst Rev. 2020; 9:CD011293.

PMID: 32926419 PMC: 8094418. DOI: 10.1002/14651858.CD011293.pub3.